Study of SGR-1505 in Mature B-Cell Neoplasms
Recruiting
Phase 1
Interventional Study
Mature B-Cell Neoplasm
Non Hodgkin Lymphoma
DLBCL
Waldenstrom Macroglobulinemia
MALT Lymphoma
Follicular Lymphoma
Pediatric-Type Follicular Lymphoma
IRF4 Gene Rearrangement
EBV-Positive DLBCL, Nos
Burkitt Lymphoma
Plasmablastic Lymphoma
High-grade B-cell Lymphoma
Primary Cutaneous Follicle Center Lymphoma
Primary Effusion Lymphoma
Mantle Cell Lymphoma
DLBCL Germinal Center B-Cell Type
Primary Mediastinal Large B Cell Lymphoma
T-Cell/Histiocyte Rich Lymphoma
ALK-Positive Large B-Cell Lymphoma
Primary Cutaneous Diffuse Large B-Cell Lymphoma
Splenic Marginal Zone Lymphoma
Chronic Lymphocytic Leukemia
Nodal Marginal Zone Lymphoma
HHV8-Positive DLBCL, Nos
Lymphoplasmacytic Lymphoma
Duodenal-Type Follicular Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 98 (estimated)
- Sponsor
- Schrödinger, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.
* Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.
* Eastern C…
Contacts